The Antifibrotic Drug Development Summit returns this November!
2025 has seen a wave of positive anti-fibrosis advances. From Agomab’s Phase 2a results in fibrostenosing Crohn’s, Boehringer’s Phase 3 IPF data, Stanford’s TGF-β work in cardiovascular fibrosis, to over $3B in deals from Lilly, GSK, and others, it’s clear the antifibrotic drug development landscape is undergoing a seismic shift.
That’s why this year’s Antifibrotic Drug Development Summit is THE place to be this November. Learn from the industry’s premier experts at the forefront of fibrosis research, gain unmissable cross-fibrosis insights, and make unmatched connections with 80+ industry leaders from Pfizer, Eli Lilly, Novartis, Takeda, and more!
Access this year’s incredible lineup of speakers
Join us this year to:
- Unlock novel targets with advances in single-cell and spatial omics, immune-stromal interactions, and cross-tissue mechanisms, featuring insights from Harvard Medical School, Gilead Sciences, and AdaptVac
- Strengthen translational confidence with precision-cut tissue slices, 3D models, and AI-driven biomarker strategies to bridge the gap between preclinical promise and clinical success
- Design winning clinical programs with lessons from recent Phase 2 data, including Resmetirom’s approval for MASH fibrosis and emerging IPF signals from GRI Bio and Redx Pharma
- Navigate the evolving landscape with expert perspectives on combination therapies, GLP-1 competition, and investor priorities to position your pipeline for partnerships and approvals
Don’t miss out – invite your colleagues to join you and take advantage of our early bird rates and group savings!
